{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:06:30Z","timestamp":1784549190820,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":35,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.rpth.2026.106789","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:37:25Z","timestamp":1781224645000},"page":"106789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanism and kinetics study of MG1113, an anti\u2013tissue factor pathway inhibitor antibody promoting hemostasis in hemophilia"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3598-8877","authenticated-orcid":false,"given":"Heechun","family":"Kwak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Ja","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5397-8762","authenticated-orcid":false,"given":"Sung Ho","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106789_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","article-title":"Haemophilia","volume":"7","author":"Berntorp","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.rpth.2026.106789_bib2","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0140-6736(24)02139-1","article-title":"Haemophilia","volume":"405","author":"Chowdary","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2026.106789_bib3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd.2018.70","article-title":"Advances and innovations in haemophilia treatment","volume":"17","author":"Peters","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.rpth.2026.106789_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/20406207261419325","article-title":"Twelve-month follow-up of a real-world, noninterventional study evaluating the impact of emicizumab on bleeding episodes, joint health, and quality of life in people with hemophilia A","volume":"17","author":"Dutta","year":"2026","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.rpth.2026.106789_bib5","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2026.106789_bib6","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106789_bib7","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood.2024027468","article-title":"Marstacimab prophylaxis in hemophilia A\/B without inhibitors: results from the phase 3 BASIS trial","volume":"146","author":"Matino","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106789_bib8","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2741\/3926","article-title":"Tissue factor pathway inhibitor: structure-function","volume":"17","author":"Broze","year":"2012","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"Suppl 1","key":"10.1016\/j.rpth.2026.106789_bib9","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1111\/jth.12897","article-title":"New insights into the biology of tissue factor pathway inhibitor","volume":"13","author":"Maroney","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106789_bib10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood.V71.2.335.335","article-title":"The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action","volume":"71","author":"Broze","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106789_bib11","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1073\/pnas.0504240103","article-title":"Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor","volume":"103","author":"Hackeng","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.rpth.2026.106789_bib12","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1074\/jbc.273.8.4378","article-title":"Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor","volume":"273","author":"Baugh","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.rpth.2026.106789_bib13","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/rth2.12438","article-title":"MG1113, a specific anti-tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia","volume":"4","author":"Kwak","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106789_bib14","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/jth.15244","article-title":"Target-mediated drug disposition modeling of an anti-TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics","volume":"19","author":"Kwak","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106789_bib15","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1182\/blood-2012-01-401620","article-title":"Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model","volume":"119","author":"Hilden","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106789_bib16","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1208\/s12248-017-0086-4","article-title":"Mechanistic modeling of the pharmacodynamic and pharmacokinetic relationship of tissue factor pathway inhibitor-neutralizing antibody (BAY 1093884) in cynomolgus monkeys","volume":"19","author":"Gu","year":"2017","journal-title":"AAPS J"},{"key":"10.1016\/j.rpth.2026.106789_bib17","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/jth.14207","article-title":"A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers","volume":"16","author":"Cardinal","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106789_bib18","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/jth.12152","article-title":"Direct inhibition of factor VIIa by TFPI and TFPI constructs","volume":"11","author":"Peraramelli","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106789_bib19","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2011-10-388512","article-title":"TFPIbeta is the GPI-anchored TFPI isoform on human endothelial cells and placental microsomes","volume":"119","author":"Girard","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106789_bib20","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1016\/S0021-9258(19)69627-4","article-title":"The role of phospholipid and factor VIIIa in the activation of bovine factor X","volume":"256","author":"van Dieijen","year":"1981","journal-title":"J Biol Chem"},{"key":"10.1016\/j.rpth.2026.106789_bib21","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.3390\/jcm11123345","article-title":"Applicability of the thrombin generation test to evaluate the hemostatic status of hemophilia A patients in daily clinical practice","volume":"11","author":"Bernardo","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.rpth.2026.106789_bib22","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2014-07-585737","article-title":"Anti-factor IXa\/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A","volume":"124","author":"Muto","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106789_bib23","article-title":"In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype","volume":"7","author":"Verhagen","year":"2023","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926034473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926034473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:24:30Z","timestamp":1784546670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926034473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2475037926034473"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106789","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanism and kinetics study of MG1113, an anti\u2013tissue factor pathway inhibitor antibody promoting hemostasis in hemophilia","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106789","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106789"}}